NeuLogiq Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder – FirstWord Pharma
المصدر: Google News — Pakistan / HEALTH
0
Views